Poolbeg Pharma (LON:POLB) Trading 13.4% Higher – Here’s Why

Shares of Poolbeg Pharma PLC (LON:POLB) were up 13.4% during trading on Tuesday . The stock traded as high as GBX 5 ($0.06) and last traded at GBX 4.42 ($0.06). Approximately 9,764,975 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 17,505,164 shares. The stock had previously closed at GBX 3.90 ($0.05).

Wall Street Analysts Forecast Growth

Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.

Poolbeg Pharma Stock Up 15.4 %

The company has a market cap of £22.50 million, a price-to-earnings ratio of -450.00 and a beta of 2.11. The business has a 50-day simple moving average of GBX 7.43 and a two-hundred day simple moving average of GBX 9.89.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.